Drug Profile

CYMS 101

Alternative Names: CYMS-101

Latest Information Update: 03 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator FibroGenesis
Class Fibroblast cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Multiple sclerosis

Most Recent Events

25 Feb 2026 Fibrogenesis plans to submit IND application to the US FDA for Multiple sclerosis in the first half of 2026.
15 Oct 2025 CYMS 101 is available for licensing as of 31 Mar 2025. https://ir.fibrobiologics.com/sec-filings/all-sec-filings/content/0001641172-25-001691/form10-k.htm
15 Oct 2025 FibroBiologics completes phase-I clinical trials in Multiple sclerosis in Mexico (IV) prior to March 2025 (FibroBiologics SEC report, March 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com